Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

The IL-23 inhibitor from AbbVie indicated for the treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic therapy or phototherapy1

Resources and access information for you and your patients during the COVID-19 pandemic


As COVID-19 continues to have an increased impact on our communities, we appreciate that this time of uncertainty may be especially challenging for you and your patients. We want you to know AbbVie is here to help. SKYRIZI Complete and our Nurse Ambassadors, Access Specialists, Access & Savings Program, and CompletePro.com are fully operational and ready to assist you and your patients: those who are just starting on SKYRIZI (risankizumab-rzaa), and those continuing treatment. For information on the Complete program, please contact:

  • SKYRIZI Complete: 1.866.SKYRIZI (1.866.759.7494)

Additionally, we understand loss of employment, compensation reductions, and insurance disruption may be a reality for some of your patients. By contacting the Complete program, you can also learn about the new myAbbVie Assist Interim Assistance program. This resource will provide medication at no charge for people who have recently lost their job and no longer have commercial insurance coverage.

Complete resources available to you and your patients

 

The Complete program is always available to support new and continuing patients with product education and access support. More information can be found at SKYRIZI Complete or by calling the number listed above.

Complete enrollment instructions

 

We understand that you and your staff may be working remotely and may not have access to a fax machine. If this is the case, the best course of action is to have patients enroll themselves.

  • To help your patients enroll via fax, please use the form and faxing instructions found at the following link: SKYRIZI.
  • For patients to enroll themselves, they can fill out and submit their enrollment form to SKYRIZI (it only takes a minute or two) or call the corresponding number listed above.

Complete resources

  • Nurse Ambassadors: Empower new and existing patients virtually

    Nurse Ambassadors are the heart of the Complete programs, providing 1:1 support to help meet the unique needs of each individual patient.

    • Ambassadors are committed to answering questions about SKYRIZI throughout the patient experience to help avoid disruptions.

    • They also answer patients' insurance questions, helping them identify potential ways to save on prescription costs, and connecting them with additional insurance expertise.

    • Our Ambassadors can even arrange for supplemental/refresher injection training, if applicable.

    • Ambassadors do not provide medical advice and are trained to direct patients to speak with their healthcare professional about any treatment-related questions, including further referrals.

  • Access Specialists: Insurance support when needed

    Our Access Specialists with expertise in payer-specific policies and processes are available to educate on payer prior authorization requirements and appeal processes, as well as provide potential options to consider based on each patient’s unique financial situation.

  • Access & Savings: Help with access and treatment affordability

    With the SKYRIZI Complete Savings Cards, eligible commercially insured patients may pay as little as $5 per prescription. Terms and Conditions apply.

  • CompletePro: Streamline Rx process for patients

    CompletePro can be used for enrollment in the Complete programs, electronic benefits verification and prior authorization, reauthorization, shipment tracking, and more to help your patients quickly start and stay on track with their prescribed treatment plan.

INDICATION AND IMPORTANT SAFETY INFORMATION for SKYRIZITM (risankizumab-rzaa)1

INDICATION

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

IMPORTANT SAFETY INFORMATION

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

Please see full Prescribing Information for SKYRIZI.

 

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

 

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines.

Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1 %) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

Please see Full Prescribing Information.

US-SKZD-190350